\-\ Texto\\:\\ \ \(0\)\
\-\ minimal\\ fever\\.\\ \\ remainder\\ of\\ examination\\ unremarkable\\.\ \(0\)\
\-\ this\\ patient\\ is\\ newly\\ diagnosed\\ and\\ undergoing\\ treatment\\.\\ \\ routine\\ surveillance\\ imaging\\ will\\ be\\ performed\\ to\\ document\\ progression\\ or\\ resolution\\.\ \(0\)\
\-\ bilateral\\ hilar\\ adenopathy\\ with\\ right\\ paratracheal\\ adenopathy\\.\\ \\ no\\ parenchymal\\ disease\\ evident\\.\ \(0\)\
\-\ sarcoid\\ \\-\\ confirmed\\ via\\ biopsy\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ lymphoma\ \(373\)\
\-\ tb\\ \\(although\\ this\\ patient\\ is\\ ppd\\ negative\\)\ \(0\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ pneumoconiosis\\ \\(silicosis\\,\\ berylliosis\\)\ \(0\)\
\-\ leukemia\ \(70\)\
\-\ 26\\ yo\\ african\\-american\\ female\\ presents\\ with\\ fever\\ and\\ \\"flu\\-like\\"\\ symptoms\\.\\ \\ no\\ unusual\\ occupational\\ exposures\\.\\ \\ acute\\ onset\\ of\\ symptoms\\.\\ \\ no\\ weight\\ loss\\.\\ \\ non\\-smoker\\.\\ hiv\\ and\\ ppd\\ negative\\.\ \(0\)\
\-\ these\\ radiographs\\ exhibit\\ the\\ classic\\ \\"1\\-2\\-3\\ sign\\"\\ of\\ bilateral\\ hilar\\ adenopathy\\ and\\ right\\ paratracheal\\ adenopathy\\ seen\\ most\\ frequently\\ in\\ sarcoidosis\\.\\ \\ as\\ this\\ patient\\ only\\ exhibits\\ adenopathy\\ without\\ evidence\\ of\\ lung\\ parenchymal\\ involvement\\,\\ this\\ would\\ be\\ categorized\\ as\\ stage\\ 1\\ sarcoidosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adenopathy\\:\\ 0\\.42034186494477094\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.25397499647840127\ \(0\)\
\-\ ppd\\:\\ 0\\.22718222998110718\ \(0\)\
\-\ paratracheal\\:\\ 0\\.22142500771731577\ \(0\)\
\-\ hilar\\:\\ 0\\.18328508506023306\ \(0\)\
\-\ parenchymal\\:\\ 0\\.17955748765418875\ \(0\)\
\-\ berylliosis\\:\\ 0\\.13787917506394468\ \(0\)\
\-\ exposures\\:\\ 0\\.13787917506394468\ \(0\)\
\-\ this\\:\\ 0\\.13736639430547362\ \(0\)\
\-\ fever\\:\\ 0\\.13552283988654273\ \(0\)\
\-\ categorized\\:\\ 0\\.1270335264749907\ \(0\)\
\-\ negative\\:\\ 0\\.12374583623359471\ \(0\)\
\-\ document\\:\\ 0\\.12233350604305628\ \(0\)\
\-\ pneumoconiosis\\:\\ 0\\.11948615296032683\ \(0\)\
\-\ silicosis\\:\\ 0\\.11863134284815087\ \(0\)\
\-\ occupational\\:\\ 0\\.1170375052938677\ \(0\)\
\-\ exhibits\\:\\ 0\\.1170375052938677\ \(0\)\
\-\ newly\\:\\ 0\\.11557664850635853\ \(0\)\
\-\ exhibit\\:\\ 0\\.11557664850635853\ \(0\)\
\-\ symptoms\\:\\ 0\\.10936433442756346\ \(0\)\
\-\ surveillance\\:\\ 0\\.10918805305609862\ \(0\)\
\-\ bilateral\\:\\ 0\\.10742418532026744\ \(0\)\
\-\ hiv\\:\\ 0\\.0988359619476313\ \(0\)\
\-\ patient\\:\\ 0\\.09751757258800592\ \(0\)\
\-\ no\\:\\ 0\\.0974992301010876\ \(0\)\
\-\ sarcoid\\:\\ 0\\.09372847822275818\ \(0\)\
\-\ progression\\:\\ 0\\.09164254253011653\ \(0\)\
\-\ leukemia\\:\\ 0\\.09128858843296744\ \(0\)\
\-\ undergoing\\:\\ 0\\.09077071431858373\ \(0\)\
\-\ unusual\\:\\ 0\\.08961874151039677\ \(0\)\
\-\ tb\\:\\ 0\\.08899295599162366\ \(0\)\
\-\ remainder\\:\\ 0\\.08794889458782608\ \(0\)\
\-\ evident\\:\\ 0\\.08590141593296965\ \(0\)\
\-\ disease\\:\\ 0\\.08390353665996207\ \(0\)\
\-\ and\\:\\ 0\\.08260650754149211\ \(0\)\
\-\ frequently\\:\\ 0\\.08230385085119461\ \(0\)\
\-\ via\\:\\ 0\\.08168542905299238\ \(0\)\
\-\ 26\\:\\ 0\\.08118624622909235\ \(0\)\
\-\ resolution\\:\\ 0\\.08108809397288418\ \(0\)\
\-\ be\\:\\ 0\\.0810843046315069\ \(0\)\
\-\ as\\:\\ 0\\.08029985974077647\ \(0\)\
\-\ stage\\:\\ 0\\.0795881297318375\ \(0\)\
\-\ of\\:\\ 0\\.07823220752708188\ \(0\)\
\-\ routine\\:\\ 0\\.07739525495696967\ \(0\)\
\-\ minimal\\:\\ 0\\.07624472360107777\ \(0\)\
\-\ classic\\:\\ 0\\.07475123257315965\ \(0\)\
\-\ confirmed\\:\\ 0\\.07369309176206429\ \(0\)\
\-\ diagnosed\\:\\ 0\\.07239471031432274\ \(0\)\
\-\ involvement\\:\\ 0\\.07233521914710947\ \(0\)\
\-\ would\\:\\ 0\\.07074654672609199\ \(0\)\
\-\ biopsy\\:\\ 0\\.07005522270136873\ \(0\)\
\-\ weight\\:\\ 0\\.06969397006967946\ \(0\)\
\-\ sign\\:\\ 0\\.06919048335576729\ \(0\)\
\-\ although\\:\\ 0\\.06803805935246537\ \(0\)\
\-\ unremarkable\\:\\ 0\\.06700052835957637\ \(0\)\
\-\ right\\:\\ 0\\.06626929065396395\ \(0\)\
\-\ radiographs\\:\\ 0\\.06482054077316039\ \(0\)\
\-\ will\\:\\ 0\\.06432483476953528\ \(0\)\
\-\ onset\\:\\ 0\\.06417508914075497\ \(0\)\
\-\ examination\\:\\ 0\\.06395284347253259\ \(0\)\
\-\ yo\\:\\ 0\\.06243759683719859\ \(0\)\
\-\ only\\:\\ 0\\.06243759683719859\ \(0\)\
\-\ loss\\:\\ 0\\.060887846200769494\ \(0\)\
\-\ lung\\:\\ 0\\.06079539146426428\ \(0\)\
\-\ lymphoma\\:\\ 0\\.05952117723472726\ \(0\)\
\-\ performed\\:\\ 0\\.059125544541693595\ \(0\)\
\-\ evidence\\:\\ 0\\.056726778885828555\ \(0\)\
\-\ these\\:\\ 0\\.05643678387489164\ \(0\)\
\-\ metastatic\\:\\ 0\\.054812752652437256\ \(0\)\
\-\ is\\:\\ 0\\.05473915716797005\ \(0\)\
\-\ acute\\:\\ 0\\.05406437211267147\ \(0\)\
\-\ without\\:\\ 0\\.052715229275781615\ \(0\)\
\-\ imaging\\:\\ 0\\.05252248660680227\ \(0\)\
\-\ most\\:\\ 0\\.05201243057289415\ \(0\)\
\-\ female\\:\\ 0\\.04822624204938049\ \(0\)\
\-\ presents\\:\\ 0\\.048076879406393026\ \(0\)\
\-\ treatment\\:\\ 0\\.04760730002377116\ \(0\)\
\-\ seen\\:\\ 0\\.047051511129906624\ \(0\)\
\-\ with\\:\\ 0\\.0391394756262188\ \(0\)\
\-\ or\\:\\ 0\\.03476776638223202\ \(0\)\
\-\ to\\:\\ 0\\.02498510547720353\ \(0\)\
\-\ in\\:\\ 0\\.024862128839790665\ \(0\)\
\-\ the\\:\\ 0\\.01994189216643206\ \(0\)\
